Therapeutics for the Treatment and Prevention of Atherosclerosis and Cardiovascular Disease
Posted Jul 11 2010 5:00pm
Description of Invention: This technology consists of peptides and peptide-analogues that enhance clearance of excess cholesterol in cells and do not exhibit the cytotoxicity that has hampered development of similar potential therapeutics.
Briefly, apolipoprotein A-1 (ApoA-1) promotes cholesterol efflux from cells and its concentration is inversely correlated with atherosclerotic events. The isolated peptidic component of ApoA-1 that acts within the cholesterol secretion pathway is therapeutic towards atherosclerosis but exhibits cytotoxic effects. In contrast, our inventors have derivatized that ApoA-1 peptide which is both less cytotoxic and more active than the underivatized component in initial studies. This potential therapeutic is similar to high density lipoprotein (HDL) therapy and may complement statin-mediated reduction of pro-atherogenic lipoproteins.
Treatment and prevention of atherosclerosis
Treatment and prevention of cardiovascular disease, coronary artery disease, heart attack, stroke, and inflammation
Therapeutic or preventative coating for a heart or vascular implant
Alternative to HDL therapy
Enhanced cytotoxicity profile
Enhanced hydrophilicity profile
Complements statin-based therapies
Oral delivery approaches in development
Development Status: Early stage with in vitro proof of concept data.
Portfolios: Internal Medicine Internal Medicine - Therapeutics
For Additional Information Please Contact: Fatima Sayyid MHPM NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325
Room 21, Rockville, MD 20852 United States Email: Fatima.Sayyid@nih.hhs.gov Phone: 301-435-4521 Fax: 301-402-0220